ACSL4 and cancer: Recently, CYP1B1 was also shown to enhance the resistance of cancer cells to ferroptosis and immunotherapy, particularly anti-PD-1, through the activation of the protein kinase C (PKC) cascade and the degradation of acyl-CoA synthetase long-chain family member 4 (ACSL4) [31].